COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanoma

被引：0

作者：

Hauschild, A. ^{[1
]}

Santinami, M. ^{[2
]}

Long, G. V. ^{[3
,4
]}

Atkinson, V. ^{[5
]}

Mandala, M. ^{[6
]}

Sileni, V. Chiarion ^{[7
]}

Nyakas, M. S. ^{[8
]}

Dutriaux, C. ^{[9
]}

Haydon, A. ^{[10
]}

Robert, C. ^{[11
]}

Mortier, L. ^{[12
]}

Schachter, J. ^{[13
]}

Ji, R. ^{[14
]}

Zhang, P. ^{[14
]}

Mookerjee, B. ^{[14
]}

Legos, J. ^{[14
]}

Kefford, R. ^{[15
,16
]}

Dummer, R. ^{[17
]}

Kirkwood, J. ^{[18
]}

机构：

[1] Univ Hosp Schleswig Holstein, Dermatol, Kiel, Germany

[2] Fdn Ist Nazl Tumori, Oncol, Milan, Italy

[3] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, Melanoma Med Oncol, Sydney, NSW, Australia

[4] Univ Sydney, Melanoma Inst Australia, Mater Hosp, Melanoma Med Oncol, Sydney, NSW, Australia

[5] Univ Queensland, Princess Alexandra Hosp, Gallipoli Med Res Fdn, Med Oncol, Brisbane, Qld, Australia

[6] Papa Giovanni XXIII Canc Ctr Hosp, Dept Oncol & Haematol, Bergamo, Italy

[7] Veneto Oncol Inst, Melanoma Oncol Unit, Padua, Italy

[8] Radiumhosp HF, Dept Oncol, Rikshosp, Oslo, Norway

[9] Hop St Andre, Ctr Hosp Univ Bordeaux, Dept Oncol Dermatol, Bordeaux, France

[10] Alfred Hosp, Med Oncol, Melbourne, Vic, Australia

[11] Inst Gustave Roussy, Dermatol, Paris, France

[12] Univ Lille, Dermatol, Lille, France

[13] Sheba Med Ctr, Ella Inst Melanoma, Oncol, Tel Hashomer, Israel

[14] Novartis Pharmaceut, Med Oncol, E Hanover, NJ USA

[15] Macquarie Univ, Melanoma Inst Australia, Westmead Hosp, Med Oncol, Sydney, NSW, Australia

[16] Univ Sydney, Sydney, NSW, Australia

[17] Univ Hosp Zurich, Dermatol, Skin Canc Ctr, Zurich, Switzerland

[18] Univ Pittsburgh, Hillman UPMC Canc Ctr, Melanoma Program, Pittsburgh, PA USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA6_PR

引用

页数：1